Drugs & Therapy

Hit Discovery Constance GmbH (HDC)

Hit Discovery Constance GmbH (HDC) is a newly-formed company, founded in 2013 as a joint venture by LDC, CD3 and Axxam. HDC is located in the former screening and sample management facilities of Takeda in Constance, Germany.

HDC offers High Throughput Screening (HTS) and Compound Management Services to customers from industry and academia. In particular, they offer automated HTS of radiometric and spectrophotometric assays (biochemical to functional cell-based) as well as automated High Content Screening (HCS) using Opera (PerkinElmer). HDC can perform the HTS against a customer’s library or their own library of 240’000 carefully selected (drug likeness, rule of five, no pains) compounds. Their compound management facility is a REMP System with a capacity of 50 million compound samples (at -20°C) that can also serve as a customer’s compound storage and logistics hub.

Competences

Compound management services, Customer’s compound storage and logistics hub, High throughput screening (HTS)

Address

Byk-Gulden-Str. 2
DE-78467 Konstanz

Phone: +49 (0)7531 - 12 731 30
Web: hit-discovery.com

Contact

Dr. Thilo Enderle
CEO / Geschäftsführer
Thilo.Enderle@hit-discovery.com